Sign Up to like & get recommendations! 0
Published in 2017 at "British Journal of Surgery"
DOI: 10.1002/bjs.10576
Abstract: Recent observations have suggested a decline in vulnerable carotid artery and iliofemoral atherosclerotic plaque characteristics over the past decade. The aim of this study was to determine whether, in the presence of clinically manifest carotid… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Clinical Laboratory Analysis"
DOI: 10.1002/jcla.22369
Abstract: This study was aimed to investigate the correlation between CYP2C19 and ABCB1 polymorphisms and the recurrence of ischemic cardiovascular adverse events in patients with coronary artery disease treated with clopidogrel. read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3593-9
Abstract: PurposeCancer chemotherapies have improved the prognosis of cancer patients in recent years; however, their side effects on the cardiovascular systems have emerged as a major concern in the field of both cardiology and oncology. In… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2020.03.025
Abstract: BACKGROUND Recent randomized control trials have described a protective cardiovascular effect of novel glucose lowering drugs in patients at high cardiovascular risk. Whether these second-line agents have similar effects in the general population is unknown.… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2021.1965988
Abstract: INTRODUCTION Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most prescribed pharmacological groups, especially in elderly patients.Areas Covered: The main GI and CV adverse events associated with NSAID use are reviewed. Risk factors and prophylactic… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12882
Abstract: The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Revista da Associacao Medica Brasileira"
DOI: 10.1590/1806-9282.63.03.261
Abstract: Objective: Determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents. Method: Analysis of original articles retrieved from the following databases: LILACS, PubMed, Cochrane Controlled Trials… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2022.37.e73
Abstract: Background Since the implementation of the nationwide coronavirus disease 2019 (COVID-19) vaccination campaign, emergency departments (EDs) have had an increasing number of patients reporting postvaccination cardiovascular adverse effects. We investigated the clinical features of patients… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.966182
Abstract: Objective The aim of this article is to assess the risk and potential mechanisms of cardiovascular adverse events in patients treated with nilotinib or imatinib by conducting a systematic review, meta-analysis and integrative bioinformatics analysis.… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.969942
Abstract: Background The reported rate of cardiovascular adverse events (CAE) caused by immune checkpoint inhibitors (ICI) is low but potentially fatal. Assess the risk of CAE in cancer patients and compare the incidence of CAE between… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2023.1116799
Abstract: Immune checkpoint inhibitors (ICIs) and Janus kinase inhibitors (JAKis) have raised concerns over serious unexpected cardiovascular adverse events. The widespread pleiotropy in genome-wide association studies offers an opportunity to identify cardiovascular risks from in-development drugs… read more here.